biology-products/synaptic-vesicles-isolation-kit-from-sigma-aldrich-1779-1/;+health+history;+medical+history.html

Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2 Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2 Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5

[0] For Release: Esco Announces 2nd North American Facility in Marietta, OH [0] Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference [0] Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products [0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES

Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2 Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2 Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 JumpStart Invests in Checkpoint Surgical 6118 1 JumpStart Invests in Checkpoint Surgical 6118 2 JumpStart Invests in Checkpoint Surgical 6118 3 Some chest pain patients wait longer than 10 minutes to see ER physician 61033 1 Some chest pain patients wait longer than 10 minutes to see ER physician 61033 2 Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 1 Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 2

[0] Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer [0] Boston Scientific Announces Pricing of $2 Billion of Senior Notes [0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer